Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

TROPiCS-03 : A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Female reproductive organs,Head and neck,LungEndometrium,Head and neck,Non-Small Cell Lung Cancer,Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II study is evaluating the effect of targeted therapy (Sacituzumab Govitecan-hziy) in people with advanced non-small cell lung cancer, head and neck squamous cell carcinoma, endometrial cancer or small cell lung cancer.
 

This trial is treating patients with non-small cell lung cancer, head and neck squamous cell carcinoma, endometrial cancer, or small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Commercial Sponsor

Gilead Sciences, Inc.

Summary

Eligible participants will receive sacituzumab govitecan-hziy (10mg/kg) intravenously on Days 1 and 8 of a 21-day cycle.

Recruiting Hospitals Read MoreRead more

Barwon Health, University Hospital Geelong
Geelong
Oncology Team
OncologyTrials@barwonhealth.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next